Jeff Jones

Stock Analyst at Oppenheimer

(0)
# 4914
Out of 5,386 analysts
112
Total ratings
Success rate
Average return
27 Stocks
Name Action PT Current % Upside Ratings Updated
KYMR Kymera Therapeutics
Maintains: Outperform
56 53
44.15 20.05% 5 Jun 27, 2025
AVBP ArriVent BioPharma
Maintains: Outperform
39 44
22.84 92.64% 3 Jun 24, 2025
YMAB Y-mAbs Therapeutics
Maintains: Outperform
20 15
4.74 216.46% 3 May 29, 2025
CMMB Chemomab Therapeutic...
Maintains: Outperform
11 10
1.17 754.7% 8 May 16, 2025
ALMS Alumis
Maintains: Outperform
26 25
3.02 727.81% 2 May 15, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
19 17
1.07 1488.79% 4 May 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
15 17
3.88 338.14% 5 May 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
85 86
31.15 176.08% 2 May 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
60 56
7.49 647.66% 9 May 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
28 18
11.2 60.71% 4 Jan 24, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Perform
n/a
n/a n/a 5 Dec 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
22 16
3.75 326.67% 7 Nov 22, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
10 9
2.35 282.98% 10 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
48 45
1.26 3471.43% 6 Aug 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Perform
n/a
n/a n/a 4 Jun 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Perform
n/a
n/a n/a 3 Apr 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
32 30
n/a n/a 3 Feb 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
13 15
n/a n/a 3 Jan 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Perform
n/a
n/a n/a 3 Jun 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
1920
n/a n/a 3 May 25, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Perform
n/a
n/a n/a 2 May 23, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
13
n/a n/a 2 May 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
15
1.07 1301.87% 5 May 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
75
n/a n/a 2 Mar 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
125 150
n/a n/a 6 Mar 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
1600 1100
2.44 44981.97% 2 Nov 17, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
193
n/a n/a 1 Jul 18, 2022